{"chunk_id": "The-Pregnancy-and-Lactation-Labeling-Rule-(PDF---656KB)__chunk_28", "source": "The-Pregnancy-and-Lactation-Labeling-Rule-(PDF---656KB)", "text": "Considerations \nClinical Considerations \nMaternal Adverse Reactions \n[TRADENAME] may increase hyperglycemia in pregnant \nwomen with diabetes.  Monitor maternal blood glucose \nlevels regularly and adjust insulin dosages as needed [see \nWarnings and Precautions (5.x)]. \n \nFDA/CDER/OND/ODEIV/DPMH 27 \n8.1 Pregnancy â€“ Clinical Considerations \nClinical Considerations \nFetal/Neonatal Adverse Reactions \nExposure to SSRIs and SNRIs, including [TRADENAME] , in \nlate pregnancy may lead to an increased risk"}